Results A total of 3637 articles were initially identified. Only 24 met eligibility criteria and were rated using the Quality of Health Economic Studies. The mean quality overall rating was 61.6, with quality scores ranging from 18 to 92. There was a higher mean quality score in the studies designed as clinical trials versus observational type designed studies (mean¼74.7(11.4), 52.6 (16.5) respectively, p¼0.002) and studies in which the statistical analyses were clearly presented versus studies in which the statistical analyses were not so clear (mean¼74.3 (12.3), 53.1 (16.1) respectively, p¼0.004). Interestingly, government funded studies exhibited a similar mean quality score to studies that were funded by industry (mean¼71.0 (15.1), 61.7 (18.5) respectively, p¼0.25). A general linear model was fitted using those independent variables which were significantly associated with quality score. The variables 'study design' and 'statistics presented clearly' were found to be jointly significant and explained nearly 70% of the variation in the dependent variable (R 2 ¼0.68). Conclusions Our analysis reveals that the methodological quality of the health economic analysis of AMD therapeutic interventions in the literature is suboptimal. There is considerable variation in methodological rigour between the articles, and we have identified several attributes that are predictive of study quality.
INTRODUCTION
Age-related macular degeneration (AMD) is a leading cause of vision loss in most developed countries, 1e7 and the exudative form of AMD may be responsible for 90% of severe vision loss from AMD. 8 The incidence, prevalence and progression of AMD increase with age. 9 Analysis of the data from the Beaver Dam Eye Study 10 found that the 15-year cumulative incidence of AMD was 14.3% for early AMD and 3.1% for late AMD. In particular, the 15-year incidence of exudative AMD was 4.4% for participants over 75 years of age but only 0.4% for participants in the 43e54 age range, a statistically significant difference. The Blue Mountains Eye Study demonstrated that over 23 000 older Australians are blind from AMD, and more than 90 000 have bilateral visual impairment due to AMD. 11 12 The incidence of AMD is similarly high in the UK where, in 2000, the cost of support services for AMD patients has been estimated at £6455 during the first year of a diagnosis of blindness and £6295 for each year thereafter. 13 AMD affects over 2.5 million Canadians.
14 Data from the Thessaloniki Eye Study revealed estimates of AMD comparable with other Western nations with a prevalence of 2.5% in Greece, 15 and similar estimates were found for Malay populations in Singapore. 16 About 88.5 million Americans will reach the age of 65 or older, and about 19 million will reach the age of 85 by 2050, 17 and it is projected that by 2050, three out of every 10 people in Europe will be over the age of 65. 18 The National Coalition on Vision Health in Canada estimates an 111% increase in AMD by 2030.
14 Visual impairment and vision loss can lead to a multitude of other problems including increased fall risks and increased dependence on care givers.
19e24 AMD is, therefore, of growing socio-economic and public health concern.
The therapeutic options available to treat AMD have grown considerably over the last two decades (figure 1). Current treatment modalities for exudative macular degeneration include periodic intravitreal injections of anti-VEGF medications (Lucentis, Avastin or Macugen), photodynamic therapy with Visudyne and (rarely) thermal ablation of the neovascular membrane with an argon or solid-state laser. In the USA, treatment with Lucentis or Avastin is currently the most commonly utilised therapy. All of these therapies are targeted towards the treatment of exudative macular degeneration.
This increase in therapeutic options has also given rise to health economic analyses of AMD therapeutic interventions in the ophthalmic literature.Such economic analyses are often cited in formulating reimbursement decisions, 25 26 consensus guidelines 9 and policy statements. 27 28 Indeed, there is currently an ongoing debate regarding the cost-effectiveness of ranibizumab (Lucentis) versus bevacizumab (Avastin) in the USA. 29 Although there is increasing interest and use of economic analysis in policy-making, few studies have been conducted, that we are aware of, to systematically review and assess the quality of the economic evaluations of AMD therapeutics. It is clearly important to critically appraise this body of literature that, increasingly, policy makers are relying on to make decisions that could potentially affect thousands of patients.
Given the growing importance of pharmacoeconomic evaluations of AMD therapeutics, we systematically reviewed the literature to identify and critically appraise the published economic analyses of AMD therapeutics. A glossary of relevant common terms used in economic analyses is shown in box 1.
Our objective was to determine whether sufficient quality evidence exists regarding economic evaluations of therapeutics for AMD. Our specific aims were to appraise the quality of health economic studies of AMD therapeutics using a validated instrument, and to identify predictors of study quality.
METHODS

Study identification and selection
We conducted a systematic search of the literature, for economic studies of AMD therapeutics published between January 1990 and March 2008; in accordance with the meta-analysis of observational studies in epidemiology guidelines. 30 The main search strategies are delineated in table 1. We performed database searches using PubMed, the National Institute of Clinical Excellence, EconLit, Health STAR, Cochrane, the Tufts CEA Registry, and the Canadian Council of Technology Assessment in Health Care. The reference lists of identified studies were also searched for potentially relevant articles.
Two investigators, who were blinded to author and source information (ie, journal and institution), independently reviewed abstracts. The full text of any articles that were flagged Figure 1 Therapeutic interventions for age-related macular degeneration by year of approval by the United States Food and Drug Administration.
Box 1 Glossary of health economic analyses and related terms
Internal validity: the study conclusions represent within the study External validity: the representativeness of generalisability of an experimental study Quality of Health Economic Studies (QHES): a validated instrument (test) that evaluates the quality of studies in health economics Dependent variable: the variable or outcome measure that the researcher believes is under the influence of some treatment or exposure Independent variable: a variable that is presumed to influence the outcome measure or dependent vairable Cost benefit analysis (CBA): an evaluative technique of making economic decisions by weighing the value of all resources consumed (expected total costs) in implementing a programme or intervention against the value of outcome (expected total benefits) in order to choose the best option; both the costs and benefits are expressed in monetary terms Cost-effectiveness analysis (CEA): a form of economic evaluation to make economic decisions by comparing the relative costs and outcomes (effects); the outcomes can be expressed using measures such as disability-adjusted life years and quality-adjusted life years Cost minimisation analysis: a relatively easy approach for making pharmacoeconomic decisions by comparing the costs of two or more drugs which have similar or identical outcomes or effectiveness rates such as equal efficacy and tolerability Cost utility (CU): a special case of CEA where the outcomes are the benefit of the health-related intervention produced in terms of the number of years lived in full health by the beneficiaries such as Quality-Adjusted Life Years Disability-Adjusted Life Year (DALY): a measure of both morbidity and mortality due to disease; includes the number of 'healthy' years of life lost to premature death as well as disability Quality-Adjusted Life Year (QALY): the number of years of life that will be added by an intervention, modified by the quality of the additional years (ie, reduced for disabilities such as blindness and need to utilise a wheelchair) Incidence: the frequency at which a finding (for example, a disease) appears in the studied population; for example, the incidence of exudative ARMD in the USA in 1990 would be the number of newly diagnosed US patients in the year 1990 Cumulative incidence: the frequency at which a finding (for example, a disease) appears in the study population, over a given period of time divided by the size of the population initially at risk Type of economic evaluation: economic evaluations involve the identification, measurement, and valuation, and then comparison of the costs and outcomes of two or more alternative interventions Perspective or economic model perspective: the viewpoint chosen for the analysisdthat is, does the model take the perspective of the payer, society, or a policy maker? Dichotomous criteria: fall into one of two different states (ie, yes or no; male or female) Joint association: two or more independent vairables have an effect on the dependent vairable together, where the independent variables cannot be interpreted separately Jointly significant: two or more independent vairables have an effect on the dependent variable together where the findings occurring by chance alone in below a certain percentage (ie, 5%)
as relevant by either of the reviewers was obtained for further review. We also retrieved the full text of any articles for which it was not possible to determine relevance from the abstract. At this initial screening stage, our objective was to identify any and all articles that described health economic analyses for any AMD therapeutic intervention. Studies were limited to English language publications and were only excluded at this stage if they lacked relevance to AMD or did not deal with human populations.
Two reviewers independently reviewed any articles that passed our initial screening criteria in order to determine whether they should be accepted for further review. Reviewers were not blinded to journal or authors at this second stage. Studies were excluded for either of the following reasons: (1) studies that were not a true economic evaluation (including cost-effectiveness analysis, costeutility analysis, costebenefit analysis or cost-minimisation analysis) and (2) studies that were descriptive or reviews only. The two reviewers independently abstracted detailed data onto a structured form, including information on the type of economic evaluation, the type of economic model, the economic model perspective (ie, payer, societal, policy maker), the specific therapeutic product for AMD that was assessed or products compared, the year of analysis if applicable, the study location (ie, country), the population studied and the type of funding source.
Evaluating the quality of the studies
We used a validated quality-scoring instrument designed to measure the quality of economic analyses. 31 32 This instrument, the Quality of Health Economic Studies (QHES), consists of 16 dichotomous criteria, with each criterion weighted. To develop the QHES, an international panel of expert health economists originally selected the 16 criteria that cover the essential domains typically used to evaluate the reliability of an economic analysis. Thus, content validity, an important criterion for the adoption of a rating instrument as scientifically sound, was established 31 32 (ie, to ascertain that the scale is representative of the content of the domains being measured). A second panel with expertise in health economics was then surveyed to generate the weighted values assigned to the criteria (ie, criterion validity was established). A prospective study was conducted to validate the QHES with a third panel of health economists. 31 32 Furthermore, QHES has been favourably evaluated in comparison with other instruments including the BMJ Guidelines, 33 the Journal of the American Medical Association User's Guide to the Medical Literature 34 35 and the Canadian guidelines for economic evaluation and drugs 36 as well as favourably assessed for reliability. 37 Since its development, the QHES has been reliably applied to evaluate health economic studies in various areas including digestive diseases, 38 physical therapy, 39 genetics services, 40 surgical treatment for obesity 41 and the use of drug-eluting stents for cardiovascular disease. 42 QHES scoring proceeds from 0 (worst quality) to 100 (highest quality), with high-quality studies considered as those scoring between 75 and 100 points. As originally developed and validated, 31 32 the quality categories are as follows: category 1 represents studies of very poor quality (scoring between 0 and 24); studies of poor quality (25e49) fall into category 2; category 3 encompasses those studies of moderate quality (scoring 50e74 points); and those studies in category 4 are considered of high quality (scoring 75e100). Both reviewers independently rated each article using the QHES. We agreed on the interpretations of the criteria contained in the QHES instrument prior to scoring any articles, to avoid different interpretation due to ambiguities.
Statistical analyses
Descriptive statistics were used to summarise quality scores. To determine predictive variables of study quality, we used the QHES as the dependent or outcome variable. We examined the following independent variables: type of economic analysis; years since publication (<3 or $3 years); number of study authors (four or less vs five or more); type of funding (government vs private); number of comparator groups (one vs more than one); study design (controlled clinical trial vs observational study); study direction (prospective vs retrospective study); whether statistical analyses (ie, whether the statistical tests and the way that the analyses were conducted using standard methods) in each study were presented clearly; whether the length of follow-up was presented; and whether sample size was explicitly stated. General linear models including analysis of variance (ANOVA) and linear regression were used to assess univariate associations of each independent variable on quality score. The F test statistic from these linear models was used to determine statistical significance, with p values <0.05 considered as an indication of statistical significance. Based on the univariate results, a parsimonious multivariate model was employed to assess the joint association of these independent variables with QHES score.
RESULTS
Our initial search of the literature yielded a total of 3637 articles (figure 2). Of these, 97 titles and abstracts met inclusion criteria for initial screening, and only 24 articles were included in the final analysis. The characteristics of the studies that were analysed are described in table 2. The mean quality score overall was 61.6, with QHES scores ranging from 18 to 92. Of the quality criteria assessed, the most commonly missing were not displaying the components or scope of the economic model clearly or transparently (73.91%); not using or not justifying the use of health outcome measures or scales (73.91%); failing to explicitly discuss the direction of bias (60.87%); and not disclosing the perspective of the analysis (60.87%) (table 3) . Overall, the intraclass correlation between the two raters was 0.807 (95% CI 0.760 to 0.966).
Our analysis of variables to identify predictors of study quality revealed that there was a higher mean quality score in the studies designed as clinical trials versus observational type designed studies (mean¼74.7 (11.4), 52.6 (16.5), respectively; p¼0.002) (table 4). Studies in which the statistical analyses were clearly presented had a higher mean quality score than papers in which the statistical analyses were not clearly presented (mean¼74. 3 (12. 3), 53.1 (16.1), respectively; p¼0.004). There was an indication of a somewhat higher mean quality score for studies designed prospectively versus retrospectively, falling just short of statistical significance (mean¼71.3 (13.5), 59.2 (19.7), respectively; p¼0.10). Government-funded studies exhibited a similar mean quality score to studies that were funded by industry (mean¼71.0 (15.1), 61.7 (18.5), respectively; p¼0.25). A general linear model was fitted using those independent variables which were significantly associated with quality score. The variables 'study design' and 'statistics presented clearly' were found to be jointly significant in the model and explained nearly 70% of the variation in the dependent variable (R 2 ¼0.68). The variable 'study design' was significant at p¼0.0009, and the variable 'statistics presented clearly' was significant at p¼0.002.
DISCUSSION
Given the increasing use of pharmacoeconomic analyses to formulate decisions regarding reimbursement policies, both by private insurers, such as in the US healthcare system 25 , and by governments, 26e28 42 43 including the UK National Institute for Health and Clinical Excellence and the Canadian Agency for Drugs and Technologies in Health, we sought to systematically review and rate the quality of published economic evaluations of AMD therapeutics. Our analysis revealed that less than onequarter of AMD therapeutic economic studies meet criteria for high quality, as assessed by a validated instrument. The mean quality rating overall was 61.6, with quality scores ranging from 18 to 92. The studies we evaluated generally fell below the threshold of 75 points on the QHES scale, below which, it has been suggested, is indicative of modest quality. 32 We found that quality appears to depend on study design and clear presentation of statistical analysis. Indeed, some 52% of studies did not appear to explicitly use sensitivity analysis to ascertain that a wide range of underlying assumptions were adequately addressed; a finding that others 31 37 have interpreted in different contexts as suggesting a lack of generalisability of the given model to relevant populations. We found that many of the studies evaluated did not clearly display the study methods and analysis of the economic model. Given that health economic studies are intended to be used in clinical decision-making and are increasingly being incorporated into practice guidelines, it is surprising that over 70% of the evaluated studies do not provide details regarding the components of the economic model. It is therefore not possible to adequately judge the validity of the model as presented. Furthermore, some 61% of studies failed to discuss the duration of bias and did not disclose the perspective of the analysis explicitly. Addressing potential biases in economic model assumptions is an important and well-accepted standard of performing health economic analysis, 31 32 particularly since variations in model assumptions can affect the overall result. Failure to explicitly discuss the direction and magnitude of potential biases may lead to overstatement of model results.
Our systematic review of the literature regarding economic analysis of AMD therapeutic interventions and quantitative assessment of study quality using the QHES is limited by several factors. One limitation lies in the use of QHES as a measure of quality. Despite being a validated measure of quality, the QHES mainly reliably measures internal validity of economic studies rather than external validity. Thus, for any given study, it may be difficult to ascertain generalisability and applicability in a particular clinical population of the pharmacoeconomic analysis. Nevertheless, the QHES remains a well-validated instrument for measuring the quality of economic studies, and is useful in shedding light on the utility of the body of economic studies for AMD therapeutic interventions. Indeed, as previously mentioned, the QHES has been reliably applied to evaluate health economic studies in various areas including digestive diseases, 38 physical therapy, 39 genetics services, 40 surgical treatment for obesity 41 and the use of drug-eluting stents for cardiovascular disease. 42 The QHES summary scores for these studies ranged from 63 to 87.1, thereby suggesting wide variation in the quality of published health economic analyses across different disease states. Second, it is possible that additional data (such as that found in the grey literature), which would have added to our study, is available in analyses that we were unable to locate. However, given that we used a broad screening strategy, it is unlikely that these data are incomplete. Third, since the reviewers were not blinded to journal or author at the second stage of review, this may be a source of bias. Fourth, it should be noted that our study is limited by our inclusion of any and all types of therapeutic interventions of AMD, as well as by differences in the characteristics of the populations and study designs in the economic analysis evaluated. Since the QHES is primarily an instrument for measuring internal validity of a given economic analysis, these differences in population characteristics and variation in study design or type of therapeutic intervention should not have a significant effect on these data. A significant strength of our study is our use of a well-validated instrument, the QHES, to evaluate the quality of the pharmacoeconomic literature on AMD therapeutic interventions. As far as we know, this quality instrument has not been used in any previous studies of AMD therapeutics interventions. Our analysis reveals a lack of standardisation among health economic studies of AMD therapeutics.
Economic models of drugs and other clinical interventions are increasingly important. Given that AMD is a chronic and progressive disease, economic modelling is useful for projecting clinical outcomes and associated long-term costs. By using a useful and easily understandable metric such as cost per quality-adjusted life year gained, for example, pharmacoeconomic models can be used for the purpose of comparing different therapeutic options.
Since such considerations are important for policy makers applying the results of models to the payer's population, it is essential that the methodology of health economic models conform to high quality standards. The use of the QHES instrument to report quantitative ratings can be helpful to decision-makers looking for a useful approach to distinguish between economic analyses. Indeed, in a survey of various individuals who regularly evaluated published health economic studies, 76% of those who did not consider themselves experts in health economics found the QHES to be a useful tool. 38 We offer several recommendations that we suggest would be helpful in improving the quality of future studies, First, we believe that the QHES criteria can be used as a starting template prior to conducting a pharmacoeconomic study to aid researchers as an a priori type of checklist for deciding what components to include in their analysis. Second, given that health economic evaluations attempt to provide hypothetical depictions of clinical reality, it is imperative that more studies provide appropriately detailed information regarding the methods used to obtain the base-case probability estimates, so that readers can judge whether they reflect valid data that are representative of clinical situations. Third, it should be noted that consensus recommendations regarding the development of economic models and reporting of results have been developed. We suggest that those engaged in conducting economic analyses and modelling should follow these guidelines. Fourth, ideally, it would be a major step forward for the field of health economics analyses, if collaborative networks of scientists engaged in economic modelling in any given area could be formed to better identify sources of variation between studies and work to improve the quality of studies. Thus, for example, a 'pharmacoeconomic AMD therapeutics collaborative network' could engage in dialogue and work collaboratively to improve modelling data and analyses. Finally, we also suggest that clinicians, decision-makers, policy-makers, journal editors and readers of health economic evaluations become familiar with and apply published guidelines for systematic reviews of economic analyses, such as the BMJ's Guideline's for Authors and Peer-Reviewers of Economic Submissions.
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In conclusion, our study reveals that the methodological quality of the health economic analysis of AMD therapeutic interventions in the literature is suboptimal. There is considerable variation in methodological rigour between articles, and we have identified several attributes that are predictive of study quality. We have also identified several factors and shortcomings that can be addressed to improve the quality of economic analysis and modelling in this field. This study may be useful for clinicians, health economists, decision and policy-makers in considering health economic analysis of AMD therapeutic interventions and working to improve the quality of economic analysis in ophthalmology.
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